Kymera Therapeutics, Inc. (KYMR)
117.39
+0.11
(+0.09%)
USD |
NASDAQ |
Sep 04, 16:00
117.47
+0.08
(+0.07%)
After-Hours: 20:00
Kymera Therapeutics SG&A Expense (TTM) : 75.75M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 75.75M |
| March 31, 2026 | 72.27M |
| December 31, 2025 | 68.19M |
| September 30, 2025 | 67.58M |
| June 30, 2025 | 65.70M |
| March 31, 2025 | 65.43M |
| December 31, 2024 | 63.53M |
| September 30, 2024 | 61.43M |
| June 30, 2024 | 60.09M |
| March 31, 2024 | 56.85M |
| December 31, 2023 | 55.04M |
| September 30, 2023 | 52.45M |
| June 30, 2023 | 48.89M |
| March 31, 2023 | 45.79M |
| Date | Value |
|---|---|
| December 31, 2022 | 43.84M |
| September 30, 2022 | 43.94M |
| June 30, 2022 | 44.05M |
| March 31, 2022 | 41.05M |
| December 31, 2021 | 36.34M |
| September 30, 2021 | 29.78M |
| June 30, 2021 | 25.95M |
| March 31, 2021 | 21.58M |
| December 31, 2020 | 18.23M |
| September 30, 2020 | 15.59M |
| June 30, 2020 | 10.25M |
| March 31, 2020 | 6.59M |
| December 31, 2019 | 4.031M |
| September 30, 2019 | 1.501M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 172.57M |
| Oncolytics Biotech, Inc. | 16.62M |
| Sangamo Therapeutics, Inc. | 31.64M |
| Sarepta Therapeutics, Inc. | 436.74M |
| Anixa Biosciences, Inc. | 6.118M |